EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 503 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... September 26, 2022 Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 Cómo mantenerse seguro e independiente durante el tratamiento contra el cáncer July 1, 2021 Load more HOT NEWS CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns What Are Clinical Practice Guidelines and How Do They Impact Care... Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... Cancer in My Community: Expanding Genetic Testing in Thailand
